Terms: = Bone cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
14 results:
1. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort.
Lankester AC; Neven B; Mahlaoui N; von Asmuth EGJ; Courteille V; Alligon M; Albert MH; Serra IB; Bader P; Balashov D; Beier R; Bertrand Y; Blanche S; Bordon V; Bredius RG; Cant A; Cavazzana M; Diaz-de-Heredia C; Dogu F; Ehlert K; Entz-Werle N; Fasth A; Ferrua F; Ferster A; Formankova R; Friedrich W; Gonzalez-Vicent M; Gozdzik J; Güngör T; Hoenig M; Ikinciogullari A; Kalwak K; Kansoy S; Kupesiz A; Lanfranchi A; Lindemans CA; Meisel R; Michel G; Miranda NAA; Moraleda J; Moshous D; Pichler H; Rao K; Sedlacek P; Slatter M; Soncini E; Speckmann C; Sundin M; Toren A; Vettenranta K; Worth A; Yeşilipek MA; Zecca M; Porta F; Schulz A; Veys P; Fischer A; Gennery AR
J Allergy Clin Immunol; 2022 May; 149(5):1744-1754.e8. PubMed ID: 34718043
[TBL] [Abstract] [Full Text] [Related]
2. Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study.
Kalicińska E; Szymczak D; Zińczuk A; Adamik B; Smiechowicz J; Skalec T; Nowicka-Suszko D; Biernat M; Bogucka-Fedorczuk A; Rybka J; Martuszewski A; Gozdzik W; Simon K; Wróbel T
Cells; 2021 May; 10(6):. PubMed ID: 34071149
[TBL] [Abstract] [Full Text] [Related]
3. Treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
4. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.
Botta C; Di Martino MT; Ciliberto D; Cucè M; Correale P; Rossi M; Tagliaferri P; Tassone P
Blood Cancer J; 2016 Dec; 6(12):e511. PubMed ID: 27983725
[TBL] [Abstract] [Full Text] [Related]
5. A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.
Martín-Antonio B; Álvarez-Laderas I; Cardesa R; Márquez-Malaver F; Baez A; Carmona M; Falantes J; Suarez-Lledo M; Fernández-Avilés F; Martínez C; Rovira M; Espigado I; Urbano-Ispizua Á
Bone Marrow Transplant; 2012 Sep; 47(9):1206-11. PubMed ID: 22231458
[TBL] [Abstract] [Full Text] [Related]
6. Elevated frequencies of CD4⁺ CD25⁺ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia.
Shenghui Z; Yixiang H; Jianbo W; Kang Y; Laixi B; Yan Z; Xi X
Int J Cancer; 2011 Sep; 129(6):1373-81. PubMed ID: 21105040
[TBL] [Abstract] [Full Text] [Related]
7. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract] [Full Text] [Related]
8. clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
Harlin H; Artz AS; Mahowald M; Rini BI; Zimmerman T; Vogelzang NJ; Gajewski TF
Bone Marrow Transplant; 2004 Mar; 33(5):491-7. PubMed ID: 14716341
[TBL] [Abstract] [Full Text] [Related]
9. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma.
Luksch R; Perotti D; Cefalo G; Gambacorti Passerini C; Massimino M; Spreafico F; Casanova M; Ferrari A; Terenziani M; Polastri D; Gambirasio F; Podda M; Bozzi F; Ravagnani F; Parmiani G; Fossati Bellani F
Tumori; 2003; 89(3):263-8. PubMed ID: 12908780
[TBL] [Abstract] [Full Text] [Related]
10. [Cellular immunotherapy for local recurrence of rectal cancer after surgery by activated lymphocyte administration--a case report].
Sasatomi T; Toh U; Miyagi Y; Ishibashi N; Araki Y; Ogata Y; Yamana H; Shirouzu K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1692-5. PubMed ID: 11708011
[TBL] [Abstract] [Full Text] [Related]
11. Immune reconstitution following allogeneic peripheral blood stem cell transplants.
Shenoy S; Mohanakumar T; Todd G; Westhoff W; Dunnigan K; Adkins DR; Brown RA; DiPersio JF
Bone Marrow Transplant; 1999 Feb; 23(4):335-46. PubMed ID: 10100577
[TBL] [Abstract] [Full Text] [Related]
12. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma.
Arun B; Slack R; Gehan E; Spitzer T; Meehan KR
Cancer; 1999 Jan; 85(1):93-9. PubMed ID: 9921979
[TBL] [Abstract] [Full Text] [Related]
13. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Gonin R; Ritz J
Blood; 1994 Aug; 84(3):964-71. PubMed ID: 8043878
[TBL] [Abstract] [Full Text] [Related]
14. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.
McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW
Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693
[TBL] [Abstract] [Full Text] [Related]
